Correlation of clinical features across GEP-defined subgroups in training (TR) and test (TE) cohorts
. | PR . | . | . | LB . | . | . | MS . | . | HY . | . | CD-1* . | . | CD-2 . | . | . | MF . | . | . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | TR . | TE . | P . | TR . | TE . | P . | TR . | TE . | TR . | TE . | TR . | TE . | TR . | TE . | P . | TR . | TE . | P . | |||||||||||
| B2M level of 339 nM or higher | 66 | 61 | NS | 35 | 41 | NS | 30 | 29 | 27 | 36 | 36 | 33 | 42 | 41 | NS | 52 | 44 | < .01 | |||||||||||
| LDH level of 190 U/L or higher | 48 | 56 | NS | 29 | 22 | NS | 26 | 38 | 26 | 18 | 36 | 17 | 40 | 29 | NS | 45 | 38 | < .01 | |||||||||||
| Albumin level of less than 35 g/L | 55 | 39 | .023 | 29 | 41 | NS | 55 | 67 | 38 | 44 | 32 | 17 | 30 | 35 | NS | 29 | 25 | .033 | |||||||||||
| Cytogenetic abnormalities | 69 | 83 | .021 | 19 | 44 | < .01 | 48 | 50 | 41 | 44 | 45 | 17 | 12 | 12 | NS | 38 | 38 | < .01 | |||||||||||
| MR1 focal lesions, 3 or more | 83 | 71 | .044 | 30 | 21 | NS | 52 | 61 | 57 | 62 | 71 | 67 | 69 | 46 | .001† | 40 | 46 | < .01 | |||||||||||
. | PR . | . | . | LB . | . | . | MS . | . | HY . | . | CD-1* . | . | CD-2 . | . | . | MF . | . | . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | TR . | TE . | P . | TR . | TE . | P . | TR . | TE . | TR . | TE . | TR . | TE . | TR . | TE . | P . | TR . | TE . | P . | |||||||||||
| B2M level of 339 nM or higher | 66 | 61 | NS | 35 | 41 | NS | 30 | 29 | 27 | 36 | 36 | 33 | 42 | 41 | NS | 52 | 44 | < .01 | |||||||||||
| LDH level of 190 U/L or higher | 48 | 56 | NS | 29 | 22 | NS | 26 | 38 | 26 | 18 | 36 | 17 | 40 | 29 | NS | 45 | 38 | < .01 | |||||||||||
| Albumin level of less than 35 g/L | 55 | 39 | .023 | 29 | 41 | NS | 55 | 67 | 38 | 44 | 32 | 17 | 30 | 35 | NS | 29 | 25 | .033 | |||||||||||
| Cytogenetic abnormalities | 69 | 83 | .021 | 19 | 44 | < .01 | 48 | 50 | 41 | 44 | 45 | 17 | 12 | 12 | NS | 38 | 38 | < .01 | |||||||||||
| MR1 focal lesions, 3 or more | 83 | 71 | .044 | 30 | 21 | NS | 52 | 61 | 57 | 62 | 71 | 67 | 69 | 46 | .001† | 40 | 46 | < .01 | |||||||||||
For the MS, HY, and MF groups, the P values were not significant; for the CD-1 group, the P values were not applicable. The total P represents the test for differences in the variable across the subgroups. This was performed on the mean of training and test set percentages. The total P was less than .01 for all groups. Values indicate the percentage of the total number of cases within each subgroup having the variable indicated. Statistical tests were performed for differences in the percentage of cases between the training and test sets.
NS indicates not significant.
Due to small number of CD-1 cases (n = 6) in the TT3 cohort, a statistical analysis was not performed. Differences were established by chi-square test.